PRTN3 and rheumatoid arthritis: As recent as 2020, Mikuls and colleagues discovered that anti-MAA antibodies are elevated prior to RA diagnosis but seemingly after ACPA and RF, possibly solidifying the role of anti-MAA antibodies in transition from preclinical to clinical severity [86].